Phase II study of patients with hormone-naive prostate cancer with a rising prostate specific antigen: granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim], thalidomide plus docetaxel
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2016
At a glance
- Drugs Sargramostim (Primary) ; Docetaxel; Thalidomide
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 24 Aug 2008 Actual patient number (9) added as reported by ClinicalTrials.gov.
- 24 Aug 2008 Trial sponsor changed from Berlex to Bayer as reported by ClinicalTrials.gov.